173 related articles for article (PubMed ID: 32681382)
1. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis.
Miura N; Mori K; Mostafaei H; Quhal F; Sari Motlagh R; Abufaraj M; Pradere B; Aydh A; Laukhtina E; D'Andrea D; Saika T; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1881-1891. PubMed ID: 32681382
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
3. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
Mori K; Miura N; Mostafaei H; Quhal F; Sari Motlagh R; Pradere B; Kimura S; Kimura T; Egawa S; Briganti A; Karakiewicz PI; Shariat SF
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):539-548. PubMed ID: 32152435
[TBL] [Abstract][Full Text] [Related]
4. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410
[TBL] [Abstract][Full Text] [Related]
6. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
7. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
[TBL] [Abstract][Full Text] [Related]
8. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Liu RJ; Hu Q; Li SY; Mao WP; Xu B; Chen M
Technol Cancer Res Treat; 2021; 20():15330338211035260. PubMed ID: 34313171
[TBL] [Abstract][Full Text] [Related]
9. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer.
Tan YG; Quek SZH; Huang HH; Ho HSS; Yuen JSP; Tay KJ; Tuan JKL; Chen K
Urol Oncol; 2021 Dec; 39(12):829.e9-829.e17. PubMed ID: 34023195
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
12. Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis.
Claps M; Petrelli F; Caffo O; Amoroso V; Roca E; Mosca A; Maines F; Barni S; Berruti A
Clin Genitourin Cancer; 2018 Jun; 16(3):165-175.e2. PubMed ID: 29454638
[TBL] [Abstract][Full Text] [Related]
13. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Janisch F; Mostafaei H; Lysenko I; Karakiewicz PI; Enikeev DV; Briganti A; Kimura S; Egawa S; Shariat SF
Clin Genitourin Cancer; 2020 Aug; 18(4):e402-e409. PubMed ID: 32007439
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
19. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
[TBL] [Abstract][Full Text] [Related]
20. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]